BIOMAT Database Logo BIOMAT Database Logo

Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. 2011

Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Department of Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033, USA. scott.walker@merck.com

The echinocandins are a class of semisynthetic natural products that target β-1,3-glucan synthase (GS). Their proven clinical efficacy combined with minimal safety issues has made the echinocandins an important asset in the management of fungal infection in a variety of patient populations. However, the echinocandins are delivered only parenterally. A screen for antifungal bioactivities combined with mechanism-of-action studies identified a class of piperazinyl-pyridazinones that target GS. The compounds exhibited in vitro activity comparable, and in some cases superior, to that of the echinocandins. The compounds inhibit GS in vitro, and there was a strong correlation between enzyme inhibition and in vitro antifungal activity. In addition, like the echinocandins, the compounds caused a leakage of cytoplasmic contents from yeast and produced a morphological response in molds characteristic of GS inhibitors. Spontaneous mutants of Saccharomyces cerevisiae with reduced susceptibility to the piperazinyl-pyridazinones had substitutions in FKS1. The sites of these substitutions were distinct from those conferring resistance to echinocandins; likewise, echinocandin-resistant isolates remained susceptible to the test compounds. Finally, we present efficacy and pharmacokinetic data on an example of the piperazinyl-pyridazinone compounds that demonstrated efficacy in a murine model of Candida glabrata infection.

UI MeSH Term Description Entries
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D005964 Glucosyltransferases Enzymes that catalyze the transfer of glucose from a nucleoside diphosphate glucose to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-. Glucosyltransferase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D012441 Saccharomyces cerevisiae A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as "baker's" or "brewer's" yeast. The dried form is used as a dietary supplement. Baker's Yeast,Brewer's Yeast,Candida robusta,S. cerevisiae,Saccharomyces capensis,Saccharomyces italicus,Saccharomyces oviformis,Saccharomyces uvarum var. melibiosus,Yeast, Baker's,Yeast, Brewer's,Baker Yeast,S cerevisiae,Baker's Yeasts,Yeast, Baker
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.
February 2000, Antimicrobial agents and chemotherapy,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1.
February 2001, Bioorganic & medicinal chemistry letters,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.
May 2001, Bioorganic & medicinal chemistry letters,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Piperazine propanol derivative as a novel antifungal targeting 1,3-beta-D-glucan synthase.
November 2005, Biological & pharmaceutical bulletin,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.
December 2015, Bioorganic & medicinal chemistry letters,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
1,3-beta-Glucan synthase: a useful target for antifungal drugs.
August 2001, Current drug targets. Infectious disorders,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.
January 2012, Journal of medicinal chemistry,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
November 2012, Bioorganic & medicinal chemistry letters,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Arborcandins A, B, C, D, E and F, novel 1,3-beta-glucan synthase inhibitors: production and biological activity.
October 2000, The Journal of antibiotics,
Scott S Walker, and Yiming Xu, and Ilias Triantafyllou, and Michelle F Waldman, and Cara Mendrick, and Nathaniel Brown, and Paul Mann, and Andrew Chau, and Reena Patel, and Nicholas Bauman, and Christine Norris, and Barry Antonacci, and Maya Gurnani, and Anthony Cacciapuoti, and Paul M McNicholas, and Samuel Wainhaus, and R Jason Herr, and Rongze Kuang, and Robert G Aslanian, and Pauline C Ting, and Todd A Black
Fungal 1,3-beta-glucan synthase.
January 1987, Methods in enzymology,
Copied contents to your clipboard!